Abstract: The present invention provides radiation synovectomy compositions for treating inflamed synovium containing a radionuclide complex bound to a substantially insoluble particle as the radiolabelled synovectomy agent in a sufficient amount of provide satisfactory synovectomy of the inflamed synovium together with a pharmaceutically acceptable vehicle, the radionuclide being a beta emitter that will substantially ablate the inflamed synovium, but not significantly damage underlying articular cartilage, the radionuclide complex being substantially kinetically stable, and if said radionuclide or radionuclide complex leaks from said joint it will be excreted from the body, the agent having a particle size such that there is essentially little or no leakage of the radionuclide complex from the joint after administration.

Abstract: Spherical particles include a core of a polymer and a metal compound covering the polymer core. These particles may be formed by homogeneously dispersing particles of a polymeric compound in an aqueous solution of a hydrolyzable metal salt to form a uniform metal layer around the spherical particles. The spherical particles can also include a core of carbon and a metal compound covering the carbon core or the particles can have a hollow core prepared by heating spherical polymer particles coated with a metal compound to a temperature of 150.degree. C. or higher in the presence of oxygen to completely decompose the polymeric compound. These spherical particles are useful in electronic materials, magnetic materials and the like.

Abstract: An interaction system, including an antibody or, antibody fragment having functional capability, which comprises a surfactant-stabilized microheterogeneous dispersion of aqueous phase in a water-immiscible medium, said aqueous phase containing an amount of said antibody or said fragment in a functional state sufficient to effect the interaction; and methods for making and for using said system.

Abstract: The present invention relates to radiopharmaceutical products used in the treatment of thyroid diseases. In particular, the present invention relates to sodium iodide .sup.131 I capsules which have increased stability and lower volatility.The objects of the present invention are achieved by providing a .sup.131 I capsule having a matrix material and antioxidant additive combination which provides for increased stability and reduced volatility of the capsule.

Abstract: Tridentate mono-anionic ligands have the structureX-A-Y-Q-Zwhere each of X and Y is independently P, As or N,Z is phenol, thiophenol or thiol, andA and Q are hydrocarbon linking groups.The ligands from cationic complexes with Technetium-99m, e.g. [Tc.sup.III K.sub.2 ].sup.+ where K is the ligand, having useful imaging properties.

Abstract: An efficient method for preparing nitrated glycerol glycol ether useful as a high energy plasticizer, by using as nitrator feed, the reaction products of an alkali metal bisulfate-catalyzed reaction of ethylene oxide and a stoichiometric excess of glycerol.

Abstract: Amide-thiolate ligands having improved metal chelate formation kinetics are disclosed. The ligands include a tertiary amine strategically located to facilitate rapid formation of an amine-amide-thiolate intermediate complex, followed by transfer of the metal to a thermodynamically stable amide-thiolate complex. The amide-thiolate ligands of the present invention may be used for post formed labeling of biological substances for use in the fields of diagnosis and therapy.

Abstract: The invention relates to conjugates composed ofa) at least one polyalcohol or a derivatized polyalcohol,b) at least one active agent,c) at least one linker andd) a protein,wherein the polyalcohol(s) or the derivatized polyalcohol(s) are polyalcohols or derivatized polyalcohols which are not recognized by the defense system of an organism as exogenous, and the protein is a protein which can be taken up by the tumor specifically or non-specifically, and is not recognized by the defense system of an organism as exogenous. These conjugates are suitable for, on the one hand, making possible a very sensitive method in nuclear medicine for the diagnosis of tumors and, on the other hand, for example also offering new methods for diagnosing tumors in X-ray diagnosis, computerized tomography, nuclear spin tomography, electron spin resonance spectroscopy or electron microscopy.

Abstract: The invention is a novel method and kit for directly radiolabeling proteins such as antibodies or antibody fragments for diagnostic and therapeutic purposes. The method comprises incubating a protein-containing solution with a solution of sodium ascorbate; adding a required quantity of reduced radionuclide to the incubated protein. A kit is also provided wherein the protein and/or reducing agents may be in lyophilized form.

Abstract: A method for therapeutic and/or diagnostic treatment of soft tumor carcinoma in mammals using certain metals or particle-emitting radionuclides complexed with hydroxyethylethylenediaminetriacetic acid is described.

Abstract: Benzalkonium chloride and benzethorium chloride are each useful in radiopharmaceutical preparations (optionally in the presence of a polymyxin or a polymyxin derivative) as bacteriostatic agents which are compatible with anti-oxidants.

Abstract: A composition useful as an imaging agent comprises a beta adrenergic receptor antagonist compound, preferably iodopindolol, to which is covalently attached an iodine radioisotope such as .sup.123 I or .sup.124 I. This composition is used in a method for radioimaging beta adrenergic receptors in a tissue, preferably brain. In particular, the method is useful with the radioimaging technique of single photon emission computed tomography (SPECT) or positron emission tomography (PET). The above composition, as well as a kit comprising a set of one or more standard radiographic images of beta adrenergic receptors, are also useful in methods for (1) diagnosing an alteration in beta adrenergic receptors in a tissue, particularly brain; (2) diagnosing suicidal depression in a subject; and (3) detecting the therapeutic normalization of beta adrenergic receptor expression in a subject.

Abstract: Microspheres for radiation therapy of a mammal which have a non-radioactive isotope which emits beta or gamma radiation of therapeutic intensity upon being irradiated. The microspheres also contain elements which do not become radioactive upon irradiation. The chemical durability of the microspheres is such that they do not release a significant amount of radiation emitting radioisotope into the mammal's system upon administration. Microspheres containing phosphorus or yttrium; and carbon, nitrogen, fluorine, sodium, magnesium, aluminum, silicon, potassium, vanadium, manganese, gallium, niobium, iodine and/or lead.

Abstract: The invention relates to compounds having the general formula I ##STR1## where A if required can contain a functional and/or activated group C for coupling to selectively concentrating compounds or can contain a selectively concentrating compound coupled via the group C. B and B' are functional groups for coordinate bonding of groups carrying metal ions. The novel compounds are for forming complexes with radioactive metal ions, more particularly rhenium and technetium isotopes, and are used in medical diagnosis and therapy.

Abstract: The present invention relates to the stabilization of radiopharmaceutical preparations and to the stabilization of components of radiopharmaceutical kits. In particular, the present invention relates to stabilization of lyophilized components of radiopharmaceutical kits by the addition of a cyclic oligosaccharide, such as, a modified or unmodified cyclodextrin, to the kit.

Abstract: The invention relates to the preparation of complexes of 99m-technetium, 186-rhenium or 188-rhenium usable as radiopharmaceutical products.For this preparation, an oxidized compound of .sup.99m Tc, .sup.186 Re or .sup.188 Re, e.g. an alkali metal or ammonium perrhenate or pertechnetate, is reacted with a first ligand chosen from the group of substituted or unsubstituted, aliphatic and aromatic phosphenes and polyphosphenes and a second nitrogenous ligand constituted by an ammonium nitride or a pharmaceutically acceptable metal or by a nitrogenous compound having a >N--N< unit, such as hydrazine, a hydrazine derivative, dithiocarbazic acid and dithiocarbazic acid derivatives.The product obtained can be used as it is as a radiopharmaceutical product or can serve as an intermediate for the preparation of other radiopharmaceutical products by exchange reaction with a third ligand, a monoclonal antibody or an antibody fragment.

Abstract: Particle-emitting radionuclides, e.g. Gd-159, Ho-166, Lu-177 and Yb-175, have been complexed with organic aminoalkylenephosphonic acids. These complexes have been found useful in compositions for the therapeutic treatment of calcific tumors or the relief of bone pain in animals.

Abstract: A method for producing microcapsules in which various coats can be applied to various cores at any desired but uniformly controllable thickness comprises the steps of:(a) providing microcapsule cores,(b) depositing resin particles uniformly onto the surfaces of the microcapsule cores to form resin particle-deposited-onto-cores,(c) putting the resin particle-deposited-onto-cores in a monodisperse state,(d) bringing the resin particle-deposited-onto-cores in the monodisperse state into contact with a solvent in which the resin of the resin particles can dissolve, and(e) drying the resin particle-deposited-onto-cores which has been brought into contact with the solvent, while kept in the monodisperse state and, then, recovering the dried cores.

Abstract: Gold sol coated with alkanethiols and alkanethiol derivatives, which provide groups on the sol available for the linking of binding moieties such as antibodies, antigens or ligands to the gold sol. Di- and tri-thiol compounds bound to gold sol also facilitate the adsorption of antibodies, antigens or ligands to the sol. The coating process, and test kits incorporating the coated sols are also included.

Abstract: Radiopharmaceuticals consisting essentially of a lipophilic, charge neutral radionuclide complex of a diaminedithiol ligand having 1-4 ester groups of the formula --A--COOR where A is a straight or branched chain alkylene of 0-10 carbon atoms and R is an alkyl group of 1-10 carbon atoms are useful in radioimaging brain perfusion in primates. Ester-substituted diaminedithiols in sterile, pharmaceutically acceptable form, and kits of the diaminedithiols and sterile, non-pyrogenic reducing agents for reducing preselected radionuclides are also provided. Technetium-99m is a preferred radionuclide.